Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.80
-0.6800-2.09%
Post-market: 31.800.00000.00%19:30 EDT
Volume:569.93K
Turnover:18.22M
Market Cap:1.89B
PE:-4.54
High:32.82
Open:32.82
Low:31.65
Close:32.48
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.47
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.84
PE(LYR):-4.47

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 29

Agios Pharmaceuticals announces annual shareholder meeting notice

Reuters
·
Apr 25

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 21

Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition

TIPRANKS
·
Apr 21

H.C. Wainwright cuts Agios target on smaller market post Novo data

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Agios Pharmaceuticals falls -23.7%

TIPRANKS
·
Apr 20

Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. -- Barrons.com

Dow Jones
·
Apr 20

Agios sinks after Novo Nordisk reports sickle cell data

TIPRANKS
·
Apr 20

Agios could come under pressure off Novo Nordisk headline, says Truist

TIPRANKS
·
Apr 20

BUZZ-Agios falls after Novo's sickle cell disease drug shows promise in late-stage study

Reuters
·
Apr 20

Agios Pharma Shares Down 15.5% Premarket After Rival Novo Nordisk Reports Late-Stage Data for Sickle Cell Disease Drug

THOMSON REUTERS
·
Apr 20

Agios Pharma (AGIO) Receives a Buy from Bank of America Securities

TIPRANKS
·
Apr 08

What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders

Simply Wall St.
·
Apr 08

Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
Apr 07

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

TIPRANKS
·
Apr 06